Biopharmaceutical research, precision medicine, and therapeutic development by Spyre Therapeutics
Spyre Therapeutics investigates SPY003 as innovative monotherapy and combination approach
Spyre Therapeutics is advancing research on SPY003, a long-acting investigational antibody designed to target IL-23, an inflammatory pathway linked to the progression of inflammatory bowel disease ...
Spyre Therapeutics presents new clinical and preclinical data for SPY001 002 003 at UEGW2026
Spyre Therapeutics announced the presentation of clinical data across its SPY001, SPY002, and SPY003 programs as well as new preclinical findings at UEGW2026. The company stated that these ...
Capital raise boosts Spyre Therapeutics funding to exceed 2 billion dollars
Spyre Therapeutics has announced a new financing round of 350 million dollars to support the advancement of its SPY072 program into late stage development for hidradenitis suppurativa. The ...
SPY003 demonstrates positive Phase 2 SKYLINE results in ulcerative colitis: Can SYRE break above $89.93?
Spyre Therapeutics reported positive mid-stage trial results for its SPY003 therapy in ulcerative colitis. The stock is up 1.9% on the day at $88.98.Spyre Therapeutics announced positive results ...
Phase 2 data shows 20 percent clinical remission for UC, Spyre Therapeutics claims
Spyre Therapeutics released positive results from its Phase 2 SKYLINE Part A trial evaluating SPY003 for ulcerative colitis (UC). The data indicated a 10.0 point reduction in the Robarts ...
Spyre Therapeutics to engage investors at three major conferences in September
Spyre Therapeutics announced its participation in three prominent industry conferences scheduled for September. The company plans to connect with the investment community at Citi BioPharma Back ...
SKYLIGHT Phase 2 trial launch lifts Spyre Therapeutics stock 1.4%
Spyre Therapeutics announced the launch of its SPY772 program and the initiation of a new clinical trial, while the stock is up 1.4% on the day at $104.91.Spyre Therapeutics announced the launch ...
Spyre Therapeutics launches SPY772 and initiates SKYLIGHT Phase 2 trial for hidradenitis suppurativa
Spyre Therapeutics, Inc. has launched its SPY772 program and begun the SKYLIGHT Phase 2 clinical trial targeting hidradenitis suppurativa (HS). The study is designed to provide proof of concept ...
Spyre Therapeutics, Inc. begins investigation of novel SPY002 antibody for persistent IBD inflammation
Spyre Therapeutics, Inc. is advancing the development of SPY002, a new monoclonal antibody designed to target TL1A, a key driver in activating immune cells and sustaining inflammation in ...
Spyre Therapeutics, Inc. earns Great Place to Work certification for 2026
Spyre Therapeutics, Inc. announced it has received the Great Place to Work certification for 2026. The company credits its supportive and rewarding environment for this achievement and ...
Spyre Therapeutics, Inc. participates in key Boston investor event
Spyre Therapeutics, Inc. will take part in the Leerink Partners Therapeutics Forum scheduled for July 14 in Boston, Massachusetts. Company representatives plan to host investor meetings ...
Spyre Therapeutics, Inc. reports 10.7-point drop in RHI score as SPY002 meets targets in ulcerative colitis trial
Spyre Therapeutics, Inc. has announced positive results from its Phase 2 SKYLINE Part A trial evaluating SPY002, an anti-TL1A therapy, in patients with moderate-to-severe ulcerative colitis. The ...
Paul Fehlner joins Spyre Therapeutics, Inc. as Chief IP Counsel with science and law expertise
Spyre Therapeutics, Inc. has announced the appointment of Paul Fehlner as Chief IP Counsel, bringing more than thirty years of experience at the intersection of science and law. Fehlner is ...
Spyre Therapeutics, Inc. secures spot on 2026 IncBestWorkplaces list for dynamic team culture
Spyre Therapeutics, Inc. has been recognized as one of the 2026 IncBestWorkplaces, underscoring its commitment to fostering a dynamic and award-winning workplace culture. The company attributes ...
Spyre Therapeutics, Inc. advances new therapies for ulcerative colitis and Crohns disease
Spyre Therapeutics, Inc. marked World IBD Day by announcing its work on next-generation combination treatments for people living with inflammatory bowel diseases, including ulcerative colitis and ...
